neuroblastoma small round blue cell tumor
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: - children with high or medium risk neuroblastoma - treated according to dutch-german protocol
Exclusion criteria
Exclusion criteria: - children with low risk neuroblastoma - children with ganglioneuroma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Determination of the value in high-risk neuroblastoma using RQ-PCR to test the presence of PHOX2b, TH, DDC, DBH, GAP43 and CHRNA3. The BM samples will be scored positive, negative or inconclusive and this outcome will be compared to the conventional testing. The MRD status will be monitored at different time points during treatment in BM and PB. The RQ-PCR data will be correlated to survival data. Primary outcomes will be overall durvival (death) and event free survival (relapse) 2. Paired BM and PB samples will be tested, scored (positive, negative and inconclusive) and compared. This study will evaluate the effectiveness of determining MRD in PB samples. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. A secondary outcome is the clinical significance of MRD positive BM or PB samples (using RQ-PCR) in non-high risk neuroblastoma patients. The BM or PB samples will be scored positive, negative and inconclusive and this outcome will be correlated to the event free or overall survival. 2. Furthermore we will use RQ-PCR testing with our set of markers to monitor the MRD status after completing therapy. The PB samples will be scored positive, negative or inconclusive and outcome will be correlated to the event free or overall survival. | — |
Countries
Netherlands
Outcome results
None listed